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~~~e~cial effects of th 
mortality and cardiac ~ct~~~ in acute 
infarction have been extensively demonstrated ( 
tokinase and urokinase, the most commonly u 
bolytic agents in clinical practice, have little 
fibrio, thus causing a severe hemostatic defect as a resu 
systemic p1asminogen activation. Therefore. 
tissue-type plasminogen activator (rt-t?A), wh 
brin-binding site, has beert developed and shown to cause 
reperfusion of occluded infarct-related arteries in 62% to 
45% of patients (8.9). Systemic fibrinolysis aad hemorrhage, 
however, have also been observed with rt-PA (101. More- 
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the agent. Therefore. the search 
ro-urokinase. a single chain ~roki~ase-type glas 
activator, has been demonstrated to exhibit also fibrin spec- 
ificity both in vitro and in viva (11-83). ~~tracoro~ary 
administration of pro-urok~~ase in humans has been shown 
to reopen occluded coronary arteries in up to 91% of patie 
(04). Reperfusion rates after the intravenous administrat 
rokinase. however. have been reported (15-W only 
groups of patients. Cowv 
ary clinical studies (15.1 
~rok~~ase after the 
ase. wherefores the 
present study was design 
and fibrin specificity of intravenous 
with acute myocardial infarction, 
synergistic interactions of pro-urok.inase and urokinase in 
humzn patients. 
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The study was approved by the ethics committee Of the 
University of Freiburg. The trial was conducted at the 
University Hospital, Freiburg, and the community hospitals 
of worms and Villingen-Schwenningen. Federal Republic of 
Germany. 
Patient s&&on. The study was considered for patients 
170 years of age who had I) typical chest pain of 230 min 
duration, and 2) electrocardiographic ST segment elevation 
of 50. I mV in at least two limb leads or 20.2 mV in at least 
two precordial (V) leads suggestive of myocardial ischemia. 
Symptoms and signs were not relieved by sublingual nitro- 
glycerin, Thrombolytic therapy had to be started within 6 h 
of symptom onset after documentation of an occluded 
(Thrombolysis in Myocardial Infarction trial (TIM11 grade 0 
or I) infarct-related artery by means of coronary angiography 
(20). The following exclusion criteria were applied: ongoing 
anticoagulant therapy: severe uncontrolled arterial hyper- 
tension (systolic pressure >2OO mm Hg or diastolic pressure 
>120 mm Hg); peptic ulceration during the last year: recent 
history of surgery; a history of coronary artery bypass 
grafting and no informed consent to participate in the study. 
Study protocol. Patients (n = 75) who qualified for the 
study and who had given informed consent underwent 
coronary angiography using the Judkins technique. After 
documentation of an occluded infarct-related artery, 0.2 to 
0.3 mg of intracoronary nitroglycerin was administered to 
exclude coronary artery spasm. On completion of the con- 
trol angiography. patients were randomized to one of two 
treatment regimens according to the presence of anterior or 
inferior myocardial infarction. First, an intravenous bolus 
injection of 10,000 U of hepdrin was administered. followed 
by a continuous infusion of 1,250 U/h of heparin. Patients 
randomized to receive high dose pro-urokinase therapy 
(group A. n = 40) received an intravenous bolus injection of 
I million U of pro-urokinase and a subsequent infusion of 8 
million U of pro-urokinase over the next hour. In the 
combined treatment group (group B, n = 35). an intravenous 
bolus injection of 0.5 million U of pro-urokinase together 
with 0.2 million U of urokinase was given, followed by an 
infusion of 4 million U of pro-urokinase over 40 min. If no 
reperfusion ITIMI grade II or 111) could be documented 75 
min after the start of the therapy, 0.2 million U of intracor- 
onary urokinase was administered. 
Coronary angiography was repeated every 15 min or 
intermittently when coronary artery reperfusion was sug- 
gested by clinical signs. Heparin therapy was continued for 
a total of 72 to 96 h. with the partial thromboplastin time 
adjusted to two times the upper limit of normal. NO concom- 
itant aspirin therapy was given. Continued anticoagulant 
therapy was the decision of the responsible physician. Cor- 
onary angiography was performed 24 to 36 h after throm- 
bolytic therapy to evaluate coronary reocclusion. 
Study agent. Human pry-u~~ki~ase was hi 
from the conditioned medium of the transforme 
line TCL-598 (Sand02 AG). The drug was s~pp! 
containing 0.5 million U of freeze-dried pro-uroki 
at 4°C and dissolved in water immediately before use. 
purified glycosylated protein migrated 
a molecular weight of approximate1 
dodecyl sulfate gel electrophoresis u 
tions. It had a latent specific activity 
as measured with the chromogenic 
Diagnostica) after activation with 
urokinase activity was C I% in the purified preparation. The 
appropriate dose of pro-urokinase was infused with a con- 
s. Citrated blood samples were col- 
ut 500 U/ml of aprotinin to prevent in 
vitro fibrinolysis. Analysis of fibrinogen (normal range 150 to 
450 mgldl) and alpha Zantiplasmin was performed. Alpha 
2-antiplasmin levels were measured utilizing chromogenic 
substrate (S-2251, Kabi-Vitrum). 
Statistics. Values are expressed as mean values 5 SD. 
Statistical comparisons of hematologic results before and 
after pro-urokinase administration were performe 
of the Student’s I test. Fisher’s exact test and the Wilcoxon 
test were used where appropriate. Comparisons between 
both treatment regimens with respect to time to reperfusion 
were carried out by the log-rank test. A p value ~0.05 was 
considered significant. 
Entry characteristics (Table I). Forty 
patients (group A) received high dose pro-urokinase therapy; 
35 patients (group B) were treated according to the combined 
regimen. There were no significant differences in baseline 
characteristics of the two groups. The duration between the 
onset of symptoms and the start of thrombolytic therapy 
averaged 199 min in group A and 190 min in group B. Control 
angiography showed TIM1 grade 0 perfusion of the infarct- 
Table 1. Clinical Characteristics of the Two Studv Grouns 
Group A Group B 
(n = 40) (n = 35) 
Men/women 3119 31/4 
Age (range) tyrl 57 (36-70) 57 (37-70) 
Anterior MI 22 19 
inferior MI 18 16 
Infarct-related artery 
TIMI 0 38 34 
TIMI I 2 I 
Duration of symptoms tminl I99 + 83 I90 + 89 
Group A = high dose pro-urokinase: Group B = low dose pro-urokinase 
plus low dose urokinase: Ml = myocardial infarction: TlMl = Thrombolysis 
in Myocardial infarction trial grade. 
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together with 0.2 
re was a tren 
million U of~~tracorooary urok’ 
late reperfusion occurring in 3 
total reperfusion rate of 80% (3 
intracoronary intervention was also performed in 1 I pa- 
tients, and repetfusion was observed in 6 additiooa~ patients, 
resulting in a total reperfusion rate of 83% (29 of 35 patients) 
si cffs. Early reocclusion (within 75 
erapy) of the infarct-related artery 
was observed in one patient in group A treated with high 
dose pro-urokinase. Reocclusion within 24 to 36 h was 
at coronary angiography in 49 patients 
whose infarct-rel artery had shown 
A patients and one group atient were documented to have 
a reoccluded vessel. T total of five patients showed 
early (n = I) or late (n = 4) reocclusion (reocclusion rate 
10%). Three group A patients and one group B 
within the first 24 h because of cardiogenic shock or intrac- 
table ventricular fibrillation. In three of the four patients. no 
reperfusion of the infarct artery had been achieved: the 
n pattents m group 
and 46% of the 
ctive values were 75%. 65%. 62% and 51% (Fig. 2). 
10 min, this difference was statistically 
cy- In this a~giogra~bica~~y controlle 
stu rate of 13% was achiev after th 
administration of 9 million U of pro-urokinase. ~e~us~o~ 
rates after administration of this new thrombolytic agent 
have been reported in only a few small studies (S-87). In a 
study 116) utilizing a total dose of 80 mg of recombinant 
pro-urokinase, 10 of 1 I ients showed reperhusion 90 min 
after the start oftherapy. ost recently, a reperfusion rate of 
47% was reported (17) in a cohort of I2 patients receiving 9 
million U of glycosylated pro-urokinase, which is equivalent 
to approximately 65 mg of the recombinant form of pro- 
c 2. Fibrinogen tmg/dl) Degradation During 
Thrombolytic Therapy 
Hours 
Control I 2 3 
.._I__ 
Group A 269 2 62 234 2 93 228 + 91 231 + 86 
Group B 294 ? 77 261 5% 264 -t 83 256 r 86 
p < 0.05 compared with control in both groups. Definitions as in Table 1. 
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Figure 2. Changes in alpha 2-antiplasmin after high dose pro- 
urokinase (open circles, n = IS) or pro-urokinase combined with low 
dose urokinase (fitted cl&s, n = 15). *p < 0.05. 
urokinase. In a recent multicenter trial (2l), a coronary 
artery patency rate of 71.8% was observed after the admin- 
istration of 80 mg of recombinant pro-urokinase. When 
pro-urokinase was administered within the first 4 h of 
symptom onset, thrombolytic efficacy appeared to be signif- 
icantly higher, resulting in a reperfusion rate of 80%. Thus, 
pro-urokinase shares the time dependence of its throm- 
bolytic efficacy ?Nith streptokinase (22). urokinase (23) and 
anisoylated plasminogen streptokinase activator complex 
(APSAC) (24). Only @PA seems to be equally effective 
when given within the first 3 h or between 4 and 6 h after the 
onset of infarction (22). 
Synergistic interactions. Another important finding of the 
present study was that the combined treatment with pro- 
urokinase and low dose urokinase was equally effective as 
high dose pro-urokinase treatment. Substantial evidence 
from experimental studies (25-28) indicates that different 
thrombolytic agents may have additive or even synergistic 
effects with regard to their thrombolytic potential. Pannell 
and Gurewich (25) reported that pro-urokinase is converted 
to its active form (high molecular weight two chain uroki- 
nase) by plasmin that is generated on the fibrin surface. In 
vitro studies (26) demonstrated that this process may be 
accelerated by a small bolus injection of urokinase, which 
exposes more fibrin binding sites for plasminogen on the 
thrombus. We demonstrated (15) coronary reperfusion in 9 
of 11 patients utilizing 6.5 million U of glycosylated pro- 
urokinase together with a bolus injection of 0.2 million U of 
urokinase, which resulted in only minimal fibrinogen degra- 
dation. In subsequent studies (19,29), patency rates of 65% 
to 75% were reported when similar combined pro-urokinase- 
urokinase treatment regimens were used. In the present 
study, the combined treatment using only half of the high 
pro-urokinase dosage (4.5 million U) was as effective as high 
dose therapy. One has to assume that both substances exert 
synergistic effects with rega 
cause the dosage of 0.2 
demonstrable independent thrombolytic effe 
dosages of 2 to 3 millio 
achieve patency rates 
combination of 4.5 million 
U of urokinase results i 
equally effective dosa 
obeyed Berenbaum’s mathematic definition of synergy (3 I), 
that is, the same thrombolyti ct can be achieved 
pro-urokinase plus low dose u e at algebraic fraction 
combinations ~1. Synergism of these two 
substances is further suggested by the fact t 
antiplasmin depletion was significantly more ra 
combined treatment group. Finally, in nine 
failed intravenous pro-urokinase administratio 
of 0.2 million U of intracoronary urokinase 
nary reperfusion within I to 3 mitt, in 
tion of pro-urokinase at the thromb 
study appears to demonstrate an additive and sy~er8~stic 
irrespective of wh 
was also administered. This value is co 
obtained by Loscalzo et al. (17). The more pronounced 
decrease in fibrinogen observed in another study (21) was 
due to the higher dosage of pro-urokinase used. As with 
other throm~olyt~c agents, clot selectivity vanishes with 
increasing pro-urokinase dosages. The minimal change in 
fibrinogen observed in this and other trials (15-17) places 
pro-urokinase in one class with rt-PA concerning fibrin 
specificity. It clearly distinguishes pro-urokinase from non- 
selective thrombolytic agents such as streptokinase, uroki- 
nase or APSAC. 
Coronary r~s~~s~o~. Early reocclusion after thrombol- 
ysis with or without combined coronary angioplasty remains 
a major problem with old thrombolytic agents like streptoki- 
nase (32-34) as well as with newer substances such as rt-PA 
(8.35). This has resulted in recommendations of prolonged 
rt-PA administration over 3 to 8 h to avoid reocclusion (35). 
In a recent trial (21) utilizing recombinant pro-urokinase, a 
low (5%) incidence of early reocclusion of the infarct-related 
artery was observed. In the present study, reocclusion 
occurred in 10% of patients, with no significant difference 
between the two treatment regimens tested. This compares 
favorably with other thrombolytic substances (8,22,24) de- 
spite the fact that in the present study, no concomitant 
aspirin therapy was given. It has been recently demonstrated 
(36) that heparin may potentiate the thrombolytic efficacy of 
natural pro-urokinase in human patients. Thus, the concom- 
itant administration of heparin during and 72 to 96 h after 
thrombolysis with pro-urokinase has to be considered to be 
of major importance with regard to both a high reperfusion 
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specificity. 
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